Lee Robert H, Bergmeier Wolfgang
McAllister Heart Institute and.
Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
J Clin Invest. 2017 Jun 1;127(6):2040-2043. doi: 10.1172/JCI94494. Epub 2017 May 15.
Diabetes mellitus is associated with an increased risk for cardiovascular disease, but the link between hyperglycemia and atherothrombotic disease is not completely understood. Patients with diabetes often show hyporesponsiveness to antiplatelet therapies, and it has been suggested that hyperreactive reticulated platelets underlie this altered therapeutic response. In this issue of the JCI, Kraakman et al. uncover a previously unknown link between hyperglycemia and enhanced platelet production and reactivity. The authors demonstrate that high blood glucose levels trigger neutrophil release of S100 calcium-binding protein A8/A9 (S100A8/A9), which binds to the receptor for advanced glycation end products (RAGE) on Kupffer cells, ultimately leading to increased thrombopoietin (TPO) production in the liver. TPO causes megakaryocyte proliferation and increased platelet production. This study demonstrates the importance of glycemic control and identifies potential therapeutic targets in the normalization of platelet numbers and function in diabetes.
糖尿病与心血管疾病风险增加相关,但高血糖与动脉粥样硬化血栓形成性疾病之间的联系尚未完全明确。糖尿病患者对抗血小板治疗往往反应低下,有人提出高反应性网织血小板是这种治疗反应改变的基础。在本期《临床研究杂志》中,克拉阿克曼等人发现了高血糖与血小板生成增加及反应性增强之间此前未知的联系。作者证明,高血糖水平会触发中性粒细胞释放S100钙结合蛋白A8/A9(S100A8/A9),该蛋白与库普弗细胞上的晚期糖基化终产物受体(RAGE)结合,最终导致肝脏中血小板生成素(TPO)产生增加。TPO会引起巨核细胞增殖并增加血小板生成。这项研究证明了血糖控制的重要性,并确定了使糖尿病患者血小板数量和功能恢复正常的潜在治疗靶点。